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To develop evidence-based international consensus recommen-
dations for the management of hip and knee osteoarthritis (OA).
Sixteen experts from 4 medical disciplines (primary care,
rheumatology, orthopaedics and evidence based medicine), 2
continents and 6 countries (USA, UK, France, Netherlands, Swe-
den and Canada) formed the guidelines development team. A
systematic review of existing guidelines for the management of
hip and knee OA published between 1945 and January 2006 was
undertaken using the validated AGREE instrument. The core
management modalities were generated based on the agree-
ment between guidelines. Evidence before 2002 was based on a
systematic review conducted by EULAR and evidence after 2002
was updated using MEDLINE, EMBASE, CINAHL, AMED, the
Cochrane Library and HTA reports. The quality of evidence was
evaluated, and where possible, effect size (ES), number needed
to treat (NNT), relative risk (RR) or odds ratio (OR) and cost
per quality adjusted life years (QALY) gained were estimated.
Consensus recommendations were produced following a Delphi
exercise and the strength of recommendation for propositions re-
lating to each modality was determined using a visual analogue
scale (VAS).
Twenty-three treatment guidelines for the management of hip
and knee OA were identiﬁed from the literature search, including
6 opinion-based (mean quality score 28%), 5 evidence-based
(41%) and 12 based on both expert opinion and research evi-
dence (51%) (p=0.001). Fifty-one different treatment modalities
were addressed by these guidelines, but only 20 were universally
recommended. Effect size (ES) for pain relief varied from treat-
ment to treatment. Overall there was no statistically signiﬁcant
difference between non-pharmacological therapies (ES=0.25,
95%CI 0.16, 0.34) and pharmacological therapies (ES=0.39,
95%CI 0.31, 0.47). Following six Delphi rounds and feedback
from OARSI members on the draft recommendations, twenty-
ﬁve recommendations, spanning non-pharmacological, pharma-
cological and surgical therapies were agreed. Strengths of rec-
ommendation and 95% conﬁdence intervals were provided.
Twenty-ﬁve recommendations were generated based on the criti-
cal appraisal of existing guidelines, systematic review of research
evidence and expert consensus. The recommendations may be
adapted for use in different countries or regions according to the
availability of treatment modalities and strength of recommenda-
tion for each modality of therapy. These recommendations will
be revised regularly following systematic review of new research
evidence as this becomes available.
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Purpose: Numerous animal models of osteoarthritis (OA) are uti-
lized by industry and academia for evaluating potential DMOADs
as well as understanding the pathophysiology of the disease.
The choice of species and mode of OA induction are dependent
upon a number of factors.
Methods: The selection of the species to be used depends
on the type of study to be performed: e.g. KO studies are re-
stricted to mice and gene proﬁling studies may be better suited
to larger animals (dogs, rabbits) in order to be able to col-
lect sufﬁcient quantities of cartilage with no contamination of
underlying bone. For the evaluation of potential DMOADs, the
method of administration and expertise in those techniques for
that species needs to be taken into account, along with com-
pound mechanism, species difference, compound availability,
metabolism and pharmacokinetics. Most OA studies are long-
term (weeks to months) and require substantial amounts of
compound to be synthesized. This in itself can make rodent
models vastly more attractive. Certain situations preclude the
use of some species. For example, a compound developed
for interaction with a human target may not be active in other
species, particularly rodents. Under these conditions, an alter-
nate model in a higher species such as dog or monkey, which
better mimic the human, should be sought. Where all the can-
didate animals differ from the human, a transgenic animal may
be created which has the human sequence, for drug-screening
purposes.
Results: The choice of OA induction, whether spontaneous,
surgical or enzymatic, depends upon the question being asked
as well as on the historic experience of the investigators. While
spontaneous OA resembles the slowly developing nature of hu-
man OA in some regards, the unknown etiology of OA in many
spontaneous models makes it challenging to obtain robust ef-
ﬁcacy. The different sourcing of a similar strain (e.g. STR/ort)
following 10 generations of breeding results in a distinct line
so that the results may be quite dissimilar. In general, the long
duration of spontaneous models requires substantial quantities
of compound. The surgical models can vary vastly in the severity
and location of the OA lesions induced. In general, we observe
that models that are more severe (e.g. ACLT in mice) result in
maximal biomechanical damage to the joint that can be chal-
lenging to ameliorate with pharmacological treatment. Therefore,
a model with more moderate progression of OA over time may
be preferred. The enzymatic models (e.g. IA collagenase in
mice) can also result in severe erosion to the cartilage, which
resembles the ACLT model in the severe erosion of the posterior
plateau to the growth plate in a signiﬁcant proportion of animals.
Conclusions: Since there is no DMOAD in the clinic, no animal
model has been validated to be predictive of human OA. Until
this situation is rectiﬁed, the evaluation of multiple models tai-
lored to the speciﬁcs of the study and target is recommended.
In this session we will discuss various rodent and non-rodent
OA models and highlight the advantages and disadvantages of
various models with speciﬁc examples where available.
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Purpose: To highlight the challenges of randomized controlled
trials of surgical interventions and to suggest approaches for
meeting these challenges.
Methods: This workshop will address key methodological ques-
